CAMP4 Therapeutics Corporation (CAMP) |
| 3.43 -0.23 (-6.28%) 10-13 16:00 |
| Open: | 3.66 |
| High: | 3.7995 |
| Low: | 3.38 |
| Volume: | 88,465 |
| Market Cap: | 215(M) |
| PE Ratio: | -1.45 |
| Exchange: | NASDAQ Global Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 4.54 |
| Resistance 1: | 4.10 |
| Pivot price: | 3.83 |
| Support 1: | 3.38 |
| Support 2: | 2.81 |
| 52w High: | 7.75 |
| 52w Low: | 2.86 |
CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.
Financials
| EPS | -2.320 |
| Book Value | -0.010 |
| PEG Ratio | 0.00 |
| Gross Profit | -0.549 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -752.11 |
| Return on Assets (ttm) | -45.3 |
| Return on Equity (ttm) | -545.8 |
Company news
Mon, 28 Sep 2026
Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day - Slideshow (NASDAQ:CAMP) 2026-09-28 - Seeking Alpha
Mon, 28 Sep 2026
Camp4 Therapeutics (Nasdaq:CAMP) - Stock Analysis - Simply Wall Street
Wed, 19 Aug 2026
Camp4 Therapeutics (NASDAQ: CAMP) insider to sell 1,738 shares - Stock Titan
Thu, 13 Aug 2026
CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Tue, 04 Aug 2026
CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement - GlobeNewswire
Mon, 27 Jul 2026
CAMP4 Therapeutics Secures Australian Regulatory Clearance - GlobeNewswire
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
